{
    "id": "6020010a1cb411341a00007c",
    "question": "Is co-loss of BRCA2-RB1 associated with better prognosis for prostate cancer patients?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the relationship between BRCA2-RB1 and prognosis for prostate cancer patients. From the provided documents, we know that BRCA2 mutations are associated with an increased risk of prostate cancer, particularly in men younger than 65 years. However, there is no direct information about the impact of BRCA2-RB1 co-loss on prostate cancer prognosis. We need to consider the potential interactions between BRCA2 and RB1 genes and their roles in cell cycle regulation, DNA repair, and transcription. The BRCA2 gene is involved in the homologous recombination DNA repair pathway, while the RB1 gene is a tumor suppressor gene that regulates cell cycle progression. The co-loss of BRCA2-RB1 may affect the function of these pathways, potentially leading to a better prognosis for prostate cancer patients. However, this is speculative and requires further research to confirm. Therefore, based on the available information, the answer is not clear, and we cannot definitively say that co-loss of BRCA2-RB1 is associated with a better prognosis for prostate cancer patients.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Surgery_Schwartz_2157",
            "title": "Surgery_Schwartz",
            "content": "BRCA1 and BRCA2 mutations may be associated with increased risks for several other cancers. BRCA1 mutations confer a fourfold increased risk for colon cancer and threefold increased risk for prostate cancer.60 BRCA2 mutations confer a fivefold increased risk for prostate cancer, sevenfold in men younger than 65 years.62 Furthermore, BRCA2 mutations confer Brunicardi_Ch10_p0305-p0354.indd 32322/02/19 2:14 PM 324BASIC CONSIDERATIONSPART Ia fivefold increased risk for gallbladder and bile duct cancers, fourfold increased risk for pancreatic cancer, and threefold increased risk for gastric cancer and malignant melanoma.62BRCA1 was the first breast cancer susceptibility gene identi-fied and has been mapped to 17q21. BRCA2, mapped to 13q12.3, was reported shortly afterward. BRCA1 and BRCA2 encode large nuclear proteins, 208 kDa and 384 kDa, respectively, that have been implicated in processes fundamental to all cells, including DNA repair and recombination, checkpoint control of the"
        },
        {
            "id": "Pathology_Robbins_1369",
            "title": "Pathology_Robbins",
            "content": "Evidence for the role of DNA repair genes in the origin of cancer also comes from the study of hereditary breast cancer. Germ line mutations in two genes, BRCA1 and BRCA2, account for 50% of cases of familial breast cancer. In addition to breast cancer, women with BRCA1 mutations have a substantially higher risk for developing epithelial ovarian cancers, and men have a slightly higher risk for developing prostate cancer. Likewise, germ line mutations in the BRCA2 gene increase the risk for developing breast cancer in both men and women, as well as cancers originating from the ovary, prostate, pancreas, bile ducts, stomach, melanocytes, and B lymphocytes. Although the functions of BRCA1 and BRCA2 have not been elucidated fully, cells with a defective version of these genes develop chromosomal breaks and severe aneuploidy. Indeed, both genes seem to function, at least in part, in the homologous recombination DNA repair pathway. For example, BRCA1 forms a complex with other proteins in"
        },
        {
            "id": "Pathology_Robbins_4169",
            "title": "Pathology_Robbins",
            "content": "Clinical and experimental observations suggest that androgens, heredity, environmental factors, and acquired somatic mutations have roles in the pathogenesis and progression of prostate cancer."
        },
        {
            "id": "Surgery_Schwartz_3802",
            "title": "Surgery_Schwartz",
            "content": "in BRCA2 families is an autosomal dominant trait and has a high penetrance. Approximately 50% of children of carriers inherit the trait. Unlike male carriers of BRCA1 mutations, men with germline mutations in BRCA2 have an estimated breast cancer risk of 6%, which represents a 100-fold increase over the risk in the general male population. BRCA2-associated breast cancers are invasive ductal carcinomas, which are more likely to be well differentiated and to express hormone receptors than are BRCA1-associated breast cancers. BRCA2-associated breast cancer has a number of distinguishing clinical features, such as an early age of onset compared with sporadic cases, a higher prevalence of bilateral breast cancer, and the presence of associ-ated cancers in some affected individuals, specifically ovarian, colon, prostate, pancreatic, gallbladder, bile duct, and stomach cancers, as well as melanoma. A number of founder mutations have been identified in BRCA2. The 6174delT mutation is found"
        },
        {
            "id": "InternalMed_Harrison_540",
            "title": "InternalMed_Harrison",
            "content": "In patients with prostate cancer and distant metastases, androgen deprivation therapy (ADT) improves survival. In patients with locally advanced disease, ADT in combination with external-beam radiation or as an adjuvant therapy (after prostatectomy and pelvic lymphadenectomy) also has been shown to improve survival. However, ADT is being increasingly used as primary therapy in men with localized disease and in men encountering biochemical recurrence without clear evidence of survival advantage. Because most men with prostate cancer die of conditions other than their primary malignancy, recognition and management of these adverse effects is paramount."
        },
        {
            "id": "Surgery_Schwartz_2158",
            "title": "Surgery_Schwartz",
            "content": "encode large nuclear proteins, 208 kDa and 384 kDa, respectively, that have been implicated in processes fundamental to all cells, including DNA repair and recombination, checkpoint control of the cell cycle, and transcription.63 Although early studies suggested that the two proteins function together as a complex, subsequent data demonstrated that they have distinct functions.64,65 In fact, breast cancers arising from BRCA1 or BRCA2 mutations are different at the molecular level and have been found to have distinct gene expression profiles.66 BRCA1-associated tumors are more likely to be estrogen receptor negative, whereas BRCA2-associated tumors are more likely to be estrogen receptor positive. Cur-rently, studies are ongoing to determine whether BRCA1 and BRCA2 status can be used to guide systemic therapy choices for breast cancer. Some targeted therapies are showing activity in BRCA mutation carriers with breast cancer such as PARP poly(ADP-ribose) polymerase-inhibitors.APC Gene"
        },
        {
            "id": "Surgery_Schwartz_3799",
            "title": "Surgery_Schwartz",
            "content": "Jul 19;92(14):1126-1135.hormone receptor negative, and have a triple receptor negative (immunohistochemical profile: ER-negative, PR-negative, and HER2-negative) or basal phenotype (based on gene expression profiling). BRCA1-associated breast cancers have a number of distinguishing clinical features, such as an early age of onset compared with sporadic cases; a higher prevalence of bilateral breast cancer; and the presence of associated cancers in some affected individuals, specifically ovarian cancer and possibly colon and prostate cancers.Several founder mutations have been identified in BRCA1. The two most common mutations are 185delAG and 5382insC, which account for 10% of all the mutations seen in BRCA1. These two mutations occur at a 10-fold higher frequency in the Ashkenazi Jewish population than in non-Jewish Caucasians. The carrier frequency of the 185delAG mutation in the Ashkenazi Jewish population is 1% and, along with the 5382insC mutation, accounts for almost all BRCA1"
        },
        {
            "id": "InternalMed_Harrison_7462",
            "title": "InternalMed_Harrison",
            "content": "proportional to disease extent at the time androgen depletion is first started, whereas the degree of PSA decline at 6 months has been shown to be prognostic. In a large-scale trial, PSA nadir proved prognostic."
        },
        {
            "id": "Pathology_Robbins_4171",
            "title": "Pathology_Robbins",
            "content": "http://ebooksmedicine.net Heredity also contributes, as there is an increased risk among first-degree relatives of patients with prostate cancer. Prostate cancer is uncommon in Asians and its incidence is highest among African-Americans and in Scandinavian countries. Aggressive, clinically significant disease is more common in African-Americans than in Caucasians. Genome-wide association studies have identified a number of genetic variants that are associated with increased risk for developing prostate cancer. Although each variant carries only a small increased risk, the effect is multiplicative, such that men with multiple risk alleles may have up to a 5-fold increase in risk compared to the general population."
        },
        {
            "id": "Pathology_Robbins_4409",
            "title": "Pathology_Robbins",
            "content": "age of onset, and susceptibility to other types of cancers differ among the many BRCA1 and BRCA2 germ-line mutations, but most carriers develop breast cancer by the age of 70 years, as compared to about 12% of women with an average risk of breast cancer. For unclear reasons, BRCA2 mutations are primarily associated with ER-positive tumors, whereas BRCA1 mutations show a strong association with triple-negative cancers ("
        },
        {
            "id": "InternalMed_Harrison_534",
            "title": "InternalMed_Harrison",
            "content": "Prostate cancer is the most common malignancy in American men, accounting for 29% of all diagnosed cancers and approximately 13% of all cancer deaths; its incidence is on the rise, partly due to increased screening with PSA. In 2013, approximately 233,000 new cases of prostate cancer were diagnosed in the United States and there were 29,480 deaths related to prostate cancer. The majority of these men have low-grade, organ-confined prostate cancer and excellent prospects of long-term survival. Substantial improvement in survival in men with prostate cancer has focused attention on the high prevalence of sexual dysfunction, physical dysfunction, and low vitality, which are important contributors to poor quality of life among patients treated for prostate cancer. The pathophysiology of these symptoms after radical prostatectomy is multifactorial, but denervation and androgen deficiency are important contributors to these symptoms."
        },
        {
            "id": "InternalMed_Harrison_6833",
            "title": "InternalMed_Harrison",
            "content": "Another tumor-suppressor gene, BRCA1, has been identified at the chromosomal locus 17q21; this gene encodes a zinc finger protein, and the protein product functions as a transcription factor and is involved in gene repair. Women who inherit a mutated allele of this gene from either parent have at least a 60\u201380% lifetime chance of developing breast cancer and about a 33% chance of developing ovarian cancer. The risk is higher among women born after 1940, presumably due to promotional effects of hormonal factors. Men who carry a mutant allele of the gene have an increased incidence of prostate cancer and breast cancer. A fourth gene, termed BRCA2, which has been localized to chromosome 13q12, is also associated with an increased incidence of breast cancer in men and women."
        },
        {
            "id": "Pathology_Robbins_4170",
            "title": "Pathology_Robbins",
            "content": "\u2022 Androgens are of central importance. Cancer of the prostate does not develop in males who are castrated before puberty, indicating that androgens somehow provide the \u201csoil,\u201d the cellular context, within which prostate cancer develops. This dependence on androgens extends to established cancers, which often regress for a time in response to surgical or chemical castration. Notably, tumors that are resistant to anti-androgen therapy often acquire androgen receptor gene amplifications or mutations that permit androgen receptors to activate the expression of their target genes despite therapy. Thus, tumors that recur in the face of anti-androgen therapies still depend on gene products regulated by androgen receptors for their growth and survival. However, while prostate cancer, like normal prostate, is dependent on androgens for its survival, there is no evidence that androgens initiate carcinogenesis, nor are androgen levels associated with prostate cancer risk."
        },
        {
            "id": "Histology_Ross_439",
            "title": "Histology_Ross",
            "content": "Understanding the details of cell-cycle regulation has had an impact on cancer research and has contributed to the development of new treatments. For instance, inactiva-tion of tumor-suppressor genes has been shown to play a role in the growth and division of cancer cells. The pro-teins encoded by these genes are used by the cell throughout several DNA-damage checkpoints. For in-stance, mutations in the breast cancer susceptibility gene 1 (BRCA-1) and breast cancer susceptibility gene 2 (BRCA-2) are associated with an increased risk for bilateral breast cancer. Both protein products of these tumor-suppressor genes\u2013namely, BRCA-1 and BRCA-2 proteins\u2013are directly involved in multiple cellular pro-cesses in response to DNA damage, including checkpoint activation, gene transcription, and repair of DNA double-strand breaks. Together with RAD-51 protein, which is involved in the homologous recombination and repair of DNA, they maintain stability of the human genome. The defective BRCA"
        },
        {
            "id": "Pathology_Robbins_4183",
            "title": "Pathology_Robbins",
            "content": "hormone (LHRH). In addition, there are many new therapies that reduce androgen synthesis or signaling in metastatic prostate cancer. Although anti-androgen therapy induces remissions, androgen-independent clones almost invariably emerge, leading to rapid disease progression and death. As discussed earlier, these mutant clones commonly continue to express many genes that in normal prostate are androgen-dependent, suggesting that mechanisms arise to reactivate androgen signaling, even in the context of androgen deprivation therapy."
        },
        {
            "id": "Gynecology_Novak_7809",
            "title": "Gynecology_Novak",
            "content": "Approximately 5% to 10% of breast cancers have an inherited basis. All inherited genes are autosomal dominant but have variable penetrance. Men carry the gene 50% of the time. The most common mutations are the BRCA1 (chromosome 17q21) and BRCA2 (chromosome 13q12-13) gene deletions. Carriers of these germline mutations have up to a 4% per year risk of developing breast cancer and a lifetime risk that ranges from 35% to 85% (4). These individuals have up to a 65% risk of developing a contralateral breast cancer. The BRCA1 mutation is associated with an increased risk of ovarian and prostate cancer, whereas BRCA2 carriers, although less common, demonstrate increased risks of male breast and prostate cancers. Both mutations are rare in the general public (0.1%) but are more commonly identified in Jews of Ashkenazi descent (1% to 2.3%) (5). Genetic testing is available and should be considered if there is a high likelihood that results will be positive and will be used to in\ufb02uence"
        },
        {
            "id": "Pathology_Robbins_4182",
            "title": "Pathology_Robbins",
            "content": "The most common treatments for clinically localized prostate cancer are radical prostatectomy and radiotherapy. The prognosis after radical prostatectomy is based on the pathologic stage, whether the margins of the resected specimens are free of tumor, and Gleason grade. The Gleason grade, clinical stage, and serum PSA values are important predictors of outcome after radiotherapy. Because many prostate cancers follow an indolent course, active surveillance (\u201cwatchful waiting\u201d) is an appropriate approach for older men, patients with significant comorbidity, or even some younger men with low serum PSA values and small, low-grade cancers. Advanced metastatic carcinoma is treated by androgen deprivation, either by orchiectomy or by administration of synthetic agonists of luteinizing hormone\u2013releasing hormone (LHRH). In addition, there are many new therapies that reduce androgen synthesis or signaling in metastatic prostate cancer. Although anti-androgen therapy induces remissions,"
        },
        {
            "id": "Gynecology_Novak_3322",
            "title": "Gynecology_Novak",
            "content": "The patient should be questioned about the following risk factors for breast cancer (see Chapter 40 for more details): Increasing age (approximately 50% of breast cancers occur after age 65) Age of menarche less than 12 years Nulliparity or first pregnancy at greater than 30 years of age Late menopause (older than 55 years of age) Family history of breast cancer (especially premenopausal or bilateral disease) Number of first-degree relatives with breast cancer and their ages when diagnosed Family history of male breast cancer Inherited conditions associated with a high risk for breast cancer, including BRCA1 and BRCA2 genes, Li-Fraumeni syndrome, Cowden\u2019s disease, ataxia telangiectasia syndrome, and Peutz-Jeghers syndrome Other malignancies (ovary, colon, and prostate) Pathology of previous breast biopsy showing atypia or lobular or ductal carcinoma Hormone therapy Alcohol consumption Postmenopausal weight gain Personal history of breast cancer"
        },
        {
            "id": "InternalMed_Harrison_7461",
            "title": "InternalMed_Harrison",
            "content": "Outcomes of Androgen Depletion The anti\u2013prostate cancer effects of the various androgen depletion/blockade strategies are similar, and the outcomes predictable: an initial response, then a period of stability in which tumor cells are dormant and nonproliferative, followed after a variable period of time by a rise in PSA and tumor regrowth as a castration-resistant lesion that for most men is invariably lethal. Androgen depletion is not curative because cells that survive castration are present when the disease is first diagnosed. Considered by disease manifestation, PSA levels return to normal in 60\u201370% of cases, and measurable lesions regress in about 50%; improvements in bone scan occur in 25% of cases, but the majority of cases remain stable. The duration of response and survival is inversely proportional to disease extent at the time androgen depletion is first started, whereas the degree of PSA decline at 6 months has been shown to be prognostic. In a large-scale trial, PSA nadir"
        },
        {
            "id": "Pathology_Robbins_4173",
            "title": "Pathology_Robbins",
            "content": "\u2022 Acquired genetic aberrations, as in other cancers, are the actual drivers of cellular transformation. Copy number variations in specific chromosomal regions and gene rearrangements are frequently seen in primary tumors. The most common gene rearrangements in prostate cancer create fusion genes consisting of the androgen-regulated promoter of the TMPRSS2 gene and the coding sequence of ETS family transcription factors. TMPRSS2-ETS fusion genes are found in approximately 40% to 60% of prostate cancers in Caucasian populations, and they occur relatively early in tumorigenesis. Notably, the prevalence of these rearrangements is lower among African-Americans and other ethnic groups. Other mutations commonly lead to activation of the PI3K/AKT signaling pathway (Chapter 6); of these, the most common are loss-of-function mutations involving the tumor suppressor PTEN, which acts as a brake on PI3K activity."
        },
        {
            "id": "Surgery_Schwartz_3796",
            "title": "Surgery_Schwartz",
            "content": "incidence among those without known BRCA mutations, there is little data to support a survival benefit. Another consideration is that while most patients are satisfied with their decision to pursue risk-reducing surgery, some are dissatisfied with the cosmetic outcomes mostly due to reconstructive issues.BRCA MutationsBRCA1. Up to 5% of breast cancers are caused by inheritance of germline mutations such as BRCA1 and BRCA2, which are inherited in an autosomal dominant fashion with varying degrees of penetrance (Table 17-7).94-100 BRCA1 is located on chromosome arm 17q, spans a genomic region of approximately 100 kilobases (kb) of DNA, and contains 22 coding exons for 1863 amino acids. Both BRCA1 and BRCA2 function as tumor-suppressor genes, and for each gene, loss of both alleles is required for the initiation of cancer. Data accumulated since the isolation of the BRCA1 gene suggest a role in transcription, cell-cycle control, and DNA damage repair pathways. More than 500 sequence"
        },
        {
            "id": "Gynecology_Novak_7459",
            "title": "Gynecology_Novak",
            "content": "60. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16:2417\u20132425. 61. Johannsson OT, Ranstam J, Borg A, et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16:397\u2013404. 62. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997\u20131003. 63. Berchuck A, Cirisano F, Lancaster JM, et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 1996;175:738\u2013746. 64. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401\u20131408. 65."
        },
        {
            "id": "Surgery_Schwartz_2156",
            "title": "Surgery_Schwartz",
            "content": "T-PLL = T-cell prolymphocytic leukemia.Adapted with permission from Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004 Mar;4(3):177-183.(Continued)mutations may be prevalent, such as in the Ashkenazi Jewish population. For a female BRCA1 mutation carrier, the cumula-tive risks of developing breast cancer and ovarian cancer by age 70 have been estimated to be 87% and 44%, respectively.60 The cumulative risks of breast cancer and ovarian cancer by age 70 in families with BRCA2 mutation have been estimated to be 84% and 27%, respectively.61 Although male breast cancer can occur with either BRCA1 or BRCA2 mutation, the majority of families (76%) with both male and female breast cancer have mutations in BRCA2.61 Besides breast and ovar-ian cancer, BRCA1 and BRCA2 mutations may be associated with increased risks for several other cancers. BRCA1 mutations confer a fourfold increased risk for colon cancer and threefold increased risk for prostate"
        },
        {
            "id": "Surgery_Schwartz_2374",
            "title": "Surgery_Schwartz",
            "content": "et al. Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:1453-1486. 113. Way BA, Kessler G. Tumour marker overview. Lab Med News-letter. 1996;4:1-7. 114. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826. 115. van \u2018t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536. 116. Cardoso F, van \u2018t Veer LJ, Bogaerts J, et al; MINDACT Inves-tigators. Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717-729. 117. Moyer VA. Screening for prostate cancer: U.S. Preventive Ser-vices Task Force recommendation statement. Ann Intern Med."
        },
        {
            "id": "Surgery_Schwartz_2139",
            "title": "Surgery_Schwartz",
            "content": "study of breast cancer in over 120,000 cases and 100,000 controls identified 65 new loci that are associated with overall breast cancer risk.50The following factors may suggest the presence of a hereditary cancer51:1. Tumor development at a much younger age than usual2. Presence of bilateral disease3. Presence of multiple primary malignancies4. Presentation of a cancer in the less affected sex (e.g., male breast cancer)5. Clustering of the same cancer type in relatives6. Occurrence of cancer in association with other conditions such as mental retardation or pathognomonic skin lesionsIt is crucial that all surgeons caring for cancer patients be aware of hereditary cancer syndromes, because a patient\u2019s genetic background has significant implications for patient and family counseling, planning of surgical therapy, and cancer screening and prevention. Some of the more commonly encoun-tered hereditary cancer syndromes are discussed here.rb1Gene. The retinoblastoma gene rb1 was the first"
        },
        {
            "id": "InternalMed_Harrison_7398",
            "title": "InternalMed_Harrison",
            "content": "In 2013, approximately 238,590 prostate cancer cases were diagnosed, and 29,720 men died from prostate cancer in the United States. The absolute number of prostate cancer deaths has decreased in the past 5 years, which has been attributed by some to the widespread use of PSA-based detection strategies. However, the benefit of screening on survival is unclear. The paradox of management is that although 1 in 6 men will eventually be diagnosed with the disease, and the disease remains the second leading cause of cancer deaths in men, only 1 man in 30 with prostate cancer will die of his disease."
        },
        {
            "id": "Pathoma_Husain_428",
            "title": "Pathoma_Husain",
            "content": "Presence of ER and PR is associated with response to antiestrogenic agents (e.g., tamoxifen); both receptors are located in the nucleus (Fig. 16.10). 3. HER2/neu amplification is associated with response to trastuzumab (Herceptin), a designer antibody directed against the HER2 receptor; HER2/neu is a growth factor receptor present on the cell surface (Fig. 16.11). 4. 'Triple-negative' tumors are negative for ER, PR, and HER2/neu and have a poor prognosis; African American women have an increased propensity to develop triple-negative carcinoma. VII. HEREDITARY BREAST CANCER A. Represents 10% of breast cancer cases B. Clinical features that suggest hereditary breast cancer include multiple first-degree relatives with breast cancer, tumor at an early age (premenopausal), and multiple tumors in a single patient. C. BRCAl and BRCA2 mutations are the most important single gene mutations associated with hereditary breast cancer. 1."
        },
        {
            "id": "Pathoma_Husain_429",
            "title": "Pathoma_Husain",
            "content": "C. BRCAl and BRCA2 mutations are the most important single gene mutations associated with hereditary breast cancer. 1. BRCAl mutation is associated with breast and ovarian carcinoma. 2. BRCA2 mutation is associated with breast carcinoma in males. D. Women with a genetic propensity to develop breast cancer may choose to undergo removal of both breasts (bilateral mastectomy) to decrease the risk of developing carcinoma. 1. A small risk for cancer remains because breast tissue sometimes extends into the axilla or subcutaneous tissue of the chest wall. VIII. MALE BREAST CANCER A. Breast cancer is rare in males (represents 1 % of all breast cancers). B. Usually presents as a subareolar mass in older males 1. Highest density of breast tissue in males is underneath the nipple. 2. C. Most common histological subtype is invasive ductal carcinoma. 1. Lobular carcinoma is rare (the male breast develops very few lobules). D. Associated with BRCA2 mutations and Klinefelter syndrome"
        },
        {
            "id": "InternalMed_Harrison_6014",
            "title": "InternalMed_Harrison",
            "content": "in prostate cancer deaths, whereas five did not. There was also an imbalance in treatment between the two study arms, with a higher proportion of men with clinically localized cancer receiving radical prostatectomy in the screening arm and receiving it at experienced referral centers."
        },
        {
            "id": "InternalMed_Harrison_538",
            "title": "InternalMed_Harrison",
            "content": "However, the role of testosterone in prostate cancer is complex. Epidemiologic studies have not revealed a consistent relationship between serum testosterone and prostate cancer. In a landmark randomized trial, testosterone therapy of older men with low testosterone did not affect intraprostatic androgen levels or the expression of androgen-dependent prostatic genes. The suppression of circulating testosterone levels by a gonadotropin-releasing hormone (GnRH) antagonist also does not affect intraprostatic androgen concentrations. Open-label trials and retrospective analyses of testosterone therapy in men with prostate cancer, who have undergone radical prostatectomy 7e-5 and have undetectable PSA levels after radical prostatectomy, have found very low rates of PSA recurrence. Even in men with high-grade prostatic intraepithelial neoplasia (HGPIN)\u2014a group at high risk of developing prostate cancer\u2014testosterone therapy for 1 year did not increase PSA or rates of prostate cancer."
        },
        {
            "id": "InternalMed_Harrison_7399",
            "title": "InternalMed_Harrison",
            "content": "Epidemiologic studies show that the risk of being diagnosed with prostate cancer increases by a factor of two if one first-degree relative is affected and by four if two or more are affected. Current estimates are that 40% of early-onset and 5\u201310% of all prostate cancers are hereditary. Prostate cancer affects ethnic groups differently. Matched for age, African-American males have both a higher incidence of prostate cancer and larger tumors and more worrisome histologic features than white males. Polymorphic variants of the AR, the cytochrome P450 C17, and the steroid 5\u03b1-reductase type II (SRD5A2) genes have been implicated in the variations in incidence."
        },
        {
            "id": "InternalMed_Harrison_7437",
            "title": "InternalMed_Harrison",
            "content": "Neoadjuvant hormone therapy before radiation therapy has the aim of decreasing the size of the prostate and, consequently, reducing the exposure of normal tissues to full-dose radiation, increasing local control rates, and decreasing the rate of systemic failure. Benign and Malignant Diseases of the Prostate 584 Short-term hormone therapy can reduce toxicities and improve local control rates, but long-term treatment (2\u20133 years) is needed to prolong the time to PSA failure and lower the risk of metastatic disease in men with high-risk cancers. The impact on survival has been less clear."
        }
    ],
    "scores": [
        0.03543620418464416,
        0.026420458355124646,
        0.02574414572802969,
        0.024945087324547303,
        0.02449863783173506,
        0.023563004402907966,
        0.022757562144354596,
        0.022241317579663446,
        0.021790272920216423,
        0.021751821751821755,
        0.02112633321871,
        0.020849986108859134,
        0.019898276519331473,
        0.018750547621133797,
        0.018304351443547716,
        0.018089960886571055,
        0.01786843769765971,
        0.017125292740046837,
        0.0170995670995671,
        0.0167075831969449,
        0.016698735568993952,
        0.016569667921944538,
        0.016420361247947456,
        0.01615581098339719,
        0.01596617442887795,
        0.01594022415940224,
        0.015753259295026557,
        0.015692307692307693,
        0.01563920712856883,
        0.015502515502515503,
        0.015494568324757003,
        0.015463337831758885
    ]
}